

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|-----------------|
| Application Number | 10599578 |
| Filing Date | 2005-03-30 |
| First Named Inventor | Malcolm King |
| Art Unit | 1616 |
| Examiner Name | Andriac M. Holt |
| Attorney Docket Number | 14628-2 |

| U.S. PATENTS | | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|------------------------|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | |
| | 1 | | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

| U.S. PATENT APPLICATION PUBLICATIONS | | | | | | | Remove |
|--------------------------------------|---------|--------------------|------------------------|------------------|---|--|------------------------|
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | |
| | 1 | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | Remove | |
|--------------------------|---------|--------------------------------------|-----------------------------|------------------------|------------------|---|--|----|
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | Ts |
| | 1 | | | | | | | |

| If you wish to add additional Foreign Patent Document citation information please click the Add button | | | | | | | Add |
|--|---------|---|--|--|--|--|------------------------|
| NON-PATENT LITERATURE DOCUMENTS | | | | | | | Remove |
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | | Ts |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|-----------------|
| Application Number | 10599578 |
| Filing Date | 2005-03-30 |
| First Named Inventor | Malcolm King |
| Art Unit | 1616 |
| Examiner Name | Andriac M. Holt |
| Attorney Docket Number | 14628-2 |

| | | |
|----|---|--------------------------|
| 1 | KING, M. et al., "Mucormodulator therapy in cystic fibrosis: balancing mucus clearability against the spread of airborne pathogens", <i>Pediatr. Pulmonol.</i> , 2004, Vol. 37, pages 77-79. | <input type="checkbox"/> |
| 2 | ZAHM, J.M. et al., "The role of mucus sol phase in clearance by simulated cough", <i>Biotherapy</i> , 1989, Vol. 26, pages 747-752. | <input type="checkbox"/> |
| 3 | RAYNAL, B.D.E. et al., "Calcium-dependent protein interactions in MUC5B provide reversible cross-links in salivary mucus", <i>J. Biol. Chem.</i> , 2003, Vol. 278, No. 31, pages 28703-28710. | <input type="checkbox"/> |
| 4 | KWANG, H.K. et al., "Inhibition of mucin release from airway goblet cells by polycationic peptides", <i>Am. J. Physiol-lung</i> , 1999, Vol 277, pages 811-815. | <input type="checkbox"/> |
| 5 | LINDEMANN, R.A., "Bacterial activation of human natural killer cells: role of cell surface lipopolysaccharide", <i>Infect. Immun.</i> , 1988, Vol. 56, No. 5, pages 1301-1308. | <input type="checkbox"/> |
| 6 | ZAYAS, G. et al., "A new paradigm in respiratory hygiene: increasing the cohesivity of airway secretions to improve cough interaction and reduce aerosol dispersion", <i>BMC Pulmonary Medicine</i> , 2005, Vol. 5, No. 11, pp. 1-12. | <input type="checkbox"/> |
| 7 | KING, M., "Mucus and its role in airway clearance and cytoprotection", <i>Airways and Lung Defence</i> , Ch. 35, pp. 409-416. | <input type="checkbox"/> |
| 8 | ZAYAS, G. et al., "A new paradigm in respiratory hygiene: modulating respiratory secretions to contain cough bioaerosol without affecting mucus clearance", <i>BMC Pulmonary Medicine</i> 2007, 7:11, 1-13. | <input type="checkbox"/> |
| 9 | RUBIN, Bruce K., "The Pharmacologic Approach to Airway Clearance: Mucoactive Agents", <i>Wake Forest University School of Medicine, Paediatr. Respir. Rev.</i> , 2006. | <input type="checkbox"/> |
| 10 | SHIBUYA, Yasuhiro, et al., "Effect of osmolality on Mucociliary Transportability and Rheology of Cystic Fibrosis and Bronchiectasis Sputum", <i>Respirology</i> 2003, 8, pp. 181-185. | <input type="checkbox"/> |
| 11 | FULORIA, M., et al., "Evaluating the Efficacy of Mucoactive Aerosol Therapy", <i>Respir. Care</i> 2000, Vol. 45, No. 7, pp. 868-873 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|----------------|
| Application Number | 10599578 |
| Filing Date | 2005-03-30 |
| First Named Inventor | Malcolm King |
| Art Unit | 1616 |
| Examiner Name | Andrae M. Holt |
| Attorney Docket Number | 14628-2 |

| | | |
|----|--|--------------------------|
| 12 | KING, M et al., "Clearance of mucus by simulated cough", J Appl Physiol 1985; 58: 1776-1782. | <input type="checkbox"/> |
| 13 | JEANNERET-GROSJEAN et al., "Sampling techniques and rheology of human bronchial mucus", Am Rev Respir Dis 1988; 137: 707-710. | <input type="checkbox"/> |
| 14 | RUBIN, BK et al., "Mucus-depleted frog palate as a model for the study of mucociliary clearance", J Appl Physiol 1990; 69: 424-429. | <input type="checkbox"/> |
| 15 | TOMKIEWICZ, RP et al., "Amiloride inhalation therapy in cystic fibrosis: Influence on ion content, hydration and rheology of sputum", Am Rev Respir Dis 1993; 148: 1002-1007. | <input type="checkbox"/> |
| 16 | HARDY, JG et al., "Lung deposition of a Nacystelyn metered dose inhaler formulation", J Aerosol Med 1993; 6:37-34. | <input type="checkbox"/> |
| 17 | KING, M et al., "Relationship with clearance funtions", Chapter 7 of: Takishima T, Shimura S, eds. Airway Secretion: Physiological Bases for the Control of Mucus Hypersecretion (Lung Biology in Health and Disease Series) New York: Marcel Dekker, 1994, 283-314. | <input type="checkbox"/> |
| 18 | FENG, W et al., "Improved clearability of cystic fibrosis sputum with dextran treatment in vitro", Am J Respir Crit Care Med 1998; 157: 710-714. | <input type="checkbox"/> |
| 19 | KING, M et al., "The Evolution of the frog palate model from mucociliary clearance", In: Baum G. ed. Cilia, Mucus and Mucociliary Interactions. New York: Marcel Dekker, 1998, 191-201. | <input type="checkbox"/> |
| 20 | FINLAY, WH et al., "Lung delivery of aerosolized dextran" Am J Respir Crit Care Med 2000; 161:91-97. | <input type="checkbox"/> |
| 21 | VANDERBIST, F et al., "Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients", Drug Dev Ind Pharm 2001; 27:205-12. | <input type="checkbox"/> |
| 22 | KING, M et al., "Pharmacological approaches to discovery and development of new mucolytic agents", Advanced Drug Delivery Review 2002;54:1475-1490. | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|-----------------|
| Application Number | 10599578 |
| Filing Date | 2005-03-30 |
| First Named Inventor | Malcolm King |
| Art Unit | 1616 |
| Examiner Name | Andriac M. Holt |
| Attorney Docket Number | 14628-2 |

| | | |
|----|--|--------------------------|
| 23 | KING, M., "Mucus, mucociliary clearance and coughing", In:Bates DV. Respiratory Function in Disease, 3rd ed Philadelphia: Saunders, 1989: 69-78. | <input type="checkbox"/> |
| 24 | KING, M., "Role of Mucus viscoelasticity in cough clearance", Biorheology 1987; 24:589-597. | <input type="checkbox"/> |
| 25 | ZAYAS, JG et al., "Tracheal mucus rheology in patients undergoing diagnostics bronchoscopy: Interrelations with smoking and cancer", Am Rev Respir Dis 1990; 141: 1107-1113. | <input type="checkbox"/> |
| 26 | WANNER, A et al., "Mucociliary clearance in the airways", Am J Respir Crit Care Med 1996; 154: 1868-1902. | <input type="checkbox"/> |
| 27 | KING, M et al., "Mucus physiology and pathophysiology.Therapeutic aspects", Chapter 13 of: Derenne JP, Whitelaw WA Similowski T, eds. Acute Respiratory Failure in COPD (Lung Biology in Health and Disease Series). New York: Marcel Dekker, 1996: 391-411. | <input type="checkbox"/> |
| 28 | KING, M et al., "Mucus controlling agents: Past and present", IN:RAu JL, ed. Aerosolized Drugs for the Respiratory Tract. Respir Care Clinics N Amer 1999: 575-594. | <input type="checkbox"/> |
| 29 | KING, M et al., "Pharmacological approaches to discovery and development of new mucolytic agents", Advanced Drug Delivery Reviews 2002; 54: 1475-1490. | <input type="checkbox"/> |
| 30 | KING, M., "Magnetic Microrheometer", In: Baraga PC, Allegra L, eds. Methods in Bronchial Mucology. New York: Raven Press, 1988, 73-83. | <input type="checkbox"/> |
| 31 | OHTAKE, K et al., "Analysis of transient and reversible effects of poly-L-arginine on the in vivo nasal absorption of FITC-dextran in rats", Journal of Controlled Release 82, 2002, 263-275. | <input type="checkbox"/> |
| 32 | MARRIOTT, C et al., "Changes in the Gel Properties of Tracheal Mucus Induced by Divalent Cations", Biorheology Vol. 16, pp. 331-337, 1979. | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|----------------|
| Application Number | 10599578 |
| Filing Date | 2005-03-30 |
| First Named Inventor | Malcolm King |
| Art Unit | 1616 |
| Examiner Name | Andrae M. Holt |
| Attorney Docket Number | 14628-2 |

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.